The burdensome condition of chemotherapy-induced peripheral neuropathy occurs with
various chemotherapeutics, including bortezomib, oxaliplatin, paclitaxel and vincristine. The …

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition
seen in patients undergoing treatment with common agents such as vincristine, paclitaxel …

Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

Chemotherapy-induced peripheral neuropathy is a common side effect of selected
chemotherapeutic agents. Previous work has suggested that patients often under report the …

Cisplatin, oxaliplatin, paclitaxel, vincristine and bortezomib are some of the most effective
drugs successfully employed (alone or in combinations) as first-line treatment for common …

Chemotherapy-induced peripheral neuropathy (CIPN) is common in patients receiving
anticancer treatment and can affect survivability and long-term quality of life of the patient …

Chemotherapy-induced neurotoxicity is a significant complication in the successful treatment
of many cancers. Neurotoxicity may develop as a consequence of treatment with platinum …

Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major concern in oncology
practice given the increasing number of cancer survivors and the lack of effective treatment …